About Mirvie
Mirvie is a company based in San Francisco (United States) founded in 2019 by Mads Melbye, Stephen Quake, and Maneesh Jain. It operates as a HealthTech. Mirvie has raised $113.7 million across 5 funding rounds from investors including Comerica, BlackRock and Khosla Ventures. The company has 35 employees as of December 31, 2022. Mirvie offers products and services including Mirvie RNA Platform and Encompass Test. Mirvie operates in a competitive market with competitors including Sera Prognostics, OncoCyte, Epic Sciences, Miroculus and Yourgene Health, among others.
- Headquarter San Francisco, United States
- Employees 35 as on 31 Dec, 2022
- Founders Mads Melbye, Stephen Quake, Maneesh Jain
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mirvie, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$113.7 M (USD)
in 5 rounds
-
Latest Funding Round
$23.7 M (USD), Series B
Jul 18, 2025
-
Investors
Comerica
& 8 more
-
Employee Count
35
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mirvie
Mirvie offers a comprehensive portfolio of products and services, including Mirvie RNA Platform and Encompass Test.
A platform predicting pregnancy complications using blood tests.
A test providing personalized insights into pregnancy health.
People of Mirvie
Unlock access to complete
Unlock access to complete
Funding Insights of Mirvie
Mirvie has successfully raised a total of $113.7M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $23.7 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mirvie
Mirvie has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Comerica, BlackRock and Khosla Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science and technology sectors
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
Investment and transformation services for entrepreneurs in technology and finance sectors.
|
Locked | Locked | Locked |
Investor details for Mirvie
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mirvie
Investment portfolio details for Mirvie
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mirvie
Detailed financials for Mirvie
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mirvie Comparisons
Peer comparison for Mirvie
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mirvie
Mirvie operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sera Prognostics, OncoCyte, Epic Sciences, Miroculus and Yourgene Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sera Prognostics is focused on women's health diagnostics.
|
|
| Locked | Locked | Locked |
Non-invasive diagnostic test solutions for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Non-invasive tests for detecting circulating tumor cells are provided.
|
|
| Locked | Locked | Locked |
MicroRNA profiling platform is developed to detect genes in samples.
|
|
| Locked | Locked | Locked |
Non-invasive prenatal genetic tests and genomic services are provided.
|
Detailed competitors of Mirvie
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mirvie
Complete news archive for Mirvie
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mirvie
Mirvie was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Mirvie is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Maneesh Jain is the current CEO of Mirvie. They have also founded this company.
Mirvie is a funded company, having raised a total of $113.7M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Mirvie is 35.
Mirvie is engaged in developing advanced health technology solutions for pregnancy care. The companys core offering, the Mirvie RNA Platform, uses a simple blood test to analyze tens of thousands of RNA messages, predicting complications like preeclampsia and preterm birth months in advance. Research and clinical validation are conducted to enhance the platforms capabilities. The solutions are aimed at enabling proactive and personalized care for pregnant women. The focus is placed on transforming pregnancy health by providing early insights into unique biological changes. The sector primarily served is healthcare, with an emphasis on maternal and fetal well-being.
Mirvie offers Mirvie RNA Platform and Encompass Test.
Mirvie has 9 investors. Key investors include Comerica, BlackRock, Khosla Ventures, Gates Foundation, and Decheng Capital.